On September 6-7, we had the pleasure of attending the 3rd Annual CAR-TCR Summit in Boston. In partnership with the CAR-TCR Summit, the Emily Whitehead Foundation hosted a silent auction for the conference attendees and raised a total $6,000!
This week marks a huge milestone for pediatric cancer research. The U.S. Food and Drug Administration (FDA) announced Wednesday that is has approved Novartis CAR-T cell therapy CTL019—now Kymriah—for pediatric patients with acute lymphoblastic leukemia (ALL)!
On August 11-12 UMI Performance, Inc. hosted their UMI Performance Cruise In & Autocross. Proceeds from the event's bake sale and t-shirt sale benefitted EWF, which Minnesota-based Viking Performance, Inc. then generously matched to bring the total raised to $2500!
On Wednesday, July 12 the FDA's Oncologic Drugs Advisory Committee convened at a meeting to discuss the pending approval of CAR-T cell therapy CTL019. Our co-founders were present at the meeting, and Tom Whitehead spoke.
On Friday, July 14 we held our third annual "Tee Off for T-Cells" charity golf tournament at Philipsburg Elks Lodge & Country Club in Philipsburg, Pa. In the last three years, "Tee Off for T-Cells" has now raised more than $150,000 for pediatric cancer research.
Emily Whitehead Foundation co-founder Tom Whitehead has been accepted as a speaker for the Oncologic Drugs Advisory Committee (ODAC) meeting on July 12, 2017. At this hearing, the U.S. Food & Drug Association (FDA) will discuss the pending approval of CAR-T cell therapy CTL019.